Evidence map›Paper›PMID 20072153›Full record

ArticleLeukemia2010

Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.

G J Leclerc, C Mou, G M Leclerc, A M Mian, J C Barredo

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Methotrexate Polyglutamates Analysis by Chromatography Methods in Biological Matrices: A Review.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Article
  15. Novel agents for the treatment of childhood acute leukemia.Therapeutic advances in hematology · 2015
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

G J LeclercDepartment of Pediatric Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101-6960, USA.
C Mou
G M Leclerc
A M Mian
J C Barredo
University of Miami · USSylvester Comprehensive Cancer Center · US

Funding

Molecular Determinants of Methotrexate in ALLR01CA098152 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BARREDO, JULIO C · 2004 to 2008
$1.5M
NCI NIH HHS R01 CA098152
6 · The paper itself

Abstract

Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure. The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS). Using DNaseI assays, we identified a hypersensitive site upstream from exon-1, suggesting chromatin remodeling could alter FPGS expression. We demonstrated that histone deacetylase-1 (HDAC1) is recruited by NFY and Sp1 transcription factors to the FPGS promoter in ALL cell lines. We examined the effect of histone deacetylase inhibitors (HDACIs) sodium butyrate and suberoylanilide hydroxamic acid (SAHA) on the expression of FPGS and other folate-related genes. HDACIs increased FPGS mRNA expression by 2- to 5-fold, whereas DHFR and TS mRNA expression was decreased. Combination treatment with MTX plus SAHA significantly increased cytotoxicity and apoptosis in B- and T-ALL cell lines as compared with each drug alone (CI<or=0.8). SAHA increased the intracellular accumulation of long-chain MTX-PG(3-7). Therefore, HDACI-induced FPGS expression increases the accumulation of MTX-PG(3-7) and cytotoxicity in ALL cell lines, which is potentiated by DHFR and TS downregulation. The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCCAAT-Binding FactorCell Line, TumorExonsGene Expression Regulation, EnzymologicHistone Deacetylase 1Histone Deacetylase InhibitorsHumansHydroxamic AcidsMethotrexatePeptide SynthasesPolyglutamic AcidPrecursor Cell Lymphoblastic Leukemia-LymphomaSp1 Transcription FactorVorinostatCCAAT-Binding Factorfolylpolyglutamate synthetaseHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase InhibitorsHydroxamic AcidsMethotrexatemethotrexate polyglutamateNFYB protein, humanPeptide SynthasesPolyglutamic AcidSp1 Transcription FactorVorinostat

Identifiers

PMID20072153
OpenAlexW2014852322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.